For all-cause mortality, the use of bDMARDs compared to csDMARDs was associated with an HR of 0.951 (95% CI: 0.894–1.011; p = 0.107), reflecting a trend toward lower mortality in the biologics group that did not reach statistical significance.
← all excerpts
Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic dmards: a propensity-matched analysis.
1
—
—